BofA notes that Dr. Martin Makary, the man who President-elect Donald Trump nominated to lead the Food and Drug Administration as its commissioner, is the Chief Medical Officer for Sesame, a telehealth company that sells compounded semaglutide. The ability for Hims & Hers and peers like Sesame to sell compounded GLP-1s will be decided by the FDA and having a leader of the agency that currently works for a company that operates as a GLP-1 compounder is “at a minimum” a positive incremental development for the future of the broader compounded GLP-1 opportunity, the analyst tells investors. While the firm maintains its Underperform rating on Hims & Hers given negative competitive developments, it acknowledges “the upside risk around GLP-1s.”
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Hunterbrook goes long Hims & Hers after short position in June
- Hims & Hers jumps after Trump nominates Dr. Marty Makary for FDA
- HIMS Stock Surges after Court Case with Eli Lilly Gets Put on Hold
- Hims & Hers Health Expands Board with New Appointment
- FDA tirzepatide status report ‘moderately positive’ for Hims & Hers, says Citi